Thank you, Mr. Chair.
That’s a great question, Mr. Hardy.
My question, I think, is probably for Mr. Tegmark.
You've spoken quite a bit about binding safety standards, and I appreciate the comparison to how we approach drug and pharmaceutical regulation.
As parliamentarians and lawmakers, where do you see us starting on this? It's one thing to look at some of the outcomes of the uses of chatbots and AI, particularly where they cross into child safety. I think those are certainly some very key and obvious areas where we need to be looking at how to ensure safety.
How else do we, in some ways, capture the breadth of how AI works across so many different fields and touches many industries and many potentially problematic areas? How do we capture that in a regulatory model that would be effective for us to address some of the harms you're raising?